Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients

Case-Control Study of Drug Monitoring of  -Lactams in Obese Critically Ill Patients

(2012) M. Hites et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing of antibiotics in obesity

(2012) Brett Janson et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients

(2012) S. Christian Cheatham et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effect of Body Mass Index on Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults: Comparison of Ertapenem with Piperacillin-Tazobactam

(2012) Tanya L. Zakrison et al.   Surgical Infections

Dosing of piperacillin/tazobactam in a morbidly obese patient

(2011) H. Deman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Estimation of creatinine clearance in morbidly obese patients

(2009) Jasmina A. Demirovic et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Pharmacokinetic issues for antibiotics in the critically ill patient

(2009) Jason A. Roberts et al.   CRITICAL CARE MEDICINE

Outcomes of Bacteremia due to Pseudomonas aeruginosa with Reduced Susceptibility to Piperacillin-Tazobactam: Implications on the Appropriateness of the Resistance Breakpoint

(2008) V. H. Tam et al.   CLINICAL INFECTIOUS DISEASES